NEJM: Efficacy of intravenous alteplase before endovascular treatment in stroke patients

The value of intravenous alteplase before endovascular therapy (EVT) in patients with acute ischemic stroke has not been extensively studied, especially in non-Asian populations .

Stroke blood vessel

Recently, a research article was published in the top medical journal NEJM.

Researchers conducted an open-label, multi-center, randomized trial in Europe, and included direct consultations in a company that can provide EVT and is eligible for intravenous alteplase treatment and Stroke patient at EVT Hospital

The primary endpoint of the study was the functional outcome of the modified Rankin scale (range 0 [no disability] to 6 [death]) at 90 days
.

The researchers evaluated the superiority of EVT alone over alteplase combined with EVT, as well as the non-inferiority of the odds ratio of the two test groups and the lower limit of the 95% confidence interval of 0.

The study analyzed 539 patients
.

The median score of the modified Rankin Scale at 90 days was 3 (interquartile range 2 to 5), with EVT alone, and 2 (interquartile range 2 to 5) in the alteplase combined with EVT group

Thus, in this randomized trial involving European patients, EVT alone was neither superior nor inferior to EVT after intravenous alteplase treatment in terms of the 90-day post-stroke disability outcome
.

The incidence of symptomatic cerebral hemorrhage was similar in the two groups

In this randomized trial involving European patients, EVT alone was neither superior nor inferior to EVT after intravenous alteplase treatment in terms of the 90-day post-stroke disability outcome